€10M financing to support disease-modifying obesity drug
Italy-based Resalis Therapeutics has closed a €10 million ($11 million) Series A financing round led by Sunstone Life Science Ventures with participation from existing investors. The company intends to use the proceeds to initiate and complete the first-in-human Phase I clinical trial and reach Phase II… Read More